US FDA Office Of New Drugs Reorg: Phase 3 Pushed To January

 
• By Michael McCaughan

The FDA has confirmed the picks to head most of the new offices in the restructured drug review organization, with one notable exception. The choice for the Office of Rare Diseases, Pediatrics, Urologic and Reproductive Medicine is still pending, while one candidate ­– Hylton Joffe – will be serving as acting OND deputy director.

reorganization
The OND reorganization remains on track for completion in February or March.

More from US FDA

More from Agency Leadership